EP3749756 - TRANSCRIPTION REGULATORY ELEMENTS AND USES THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 13.11.2020 Database last updated on 22.08.2024 | |
Former | The international publication has been made Status updated on 10.08.2019 | Most recent event Tooltip | 27.02.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Audentes Therapeutics, Inc. 600 California Street 17th Floor San Francisco, CA 94108 / US | [2020/51] | Inventor(s) | 01 /
GRAY, John T. 101 Montgomery Street Suite 2650 San Francisco, CA 94104 / US | [2020/51] | Representative(s) | Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE | [2020/51] | Application number, filing date | 19748361.3 | 05.02.2019 | [2020/51] | WO2019US16692 | Priority number, date | US201862626561P | 05.02.2018 Original published format: US 201862626561 P | [2020/51] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019153009 | Date: | 08.08.2019 | Language: | EN | [2019/32] | Type: | A1 Application with search report | No.: | EP3749756 | Date: | 16.12.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 08.08.2019 takes the place of the publication of the European patent application. | [2020/51] | Search report(s) | International search report - published on: | US | 08.08.2019 | (Supplementary) European search report - dispatched on: | EP | 08.11.2021 | Classification | IPC: | C12N7/00, C12N15/86, C12Q1/70 | [2020/51] | CPC: |
C12N15/86 (EP,US);
A61K48/0058 (EP,US);
A61K48/005 (EP);
A61P3/00 (US);
C12N7/00 (US);
C12N2750/14143 (EP,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/51] | Extension states | BA | 17.08.2020 | ME | 17.08.2020 | Validation states | KH | 17.08.2020 | MA | 17.08.2020 | MD | 17.08.2020 | TN | 17.08.2020 | Title | German: | TRANSKRIPTIONSREGULIERENDE ELEMENTE UND VERWENDUNGEN DAVON | [2020/51] | English: | TRANSCRIPTION REGULATORY ELEMENTS AND USES THEREOF | [2020/51] | French: | ÉLÉMENTS DE RÉGULATION DE LA TRANSCRIPTION ET UTILISATIONS ASSOCIÉES | [2020/51] | Entry into regional phase | 17.08.2020 | National basic fee paid | 17.08.2020 | Search fee paid | 17.08.2020 | Designation fee(s) paid | 17.08.2020 | Examination fee paid | Examination procedure | 17.08.2020 | Examination requested [2020/51] | 29.06.2022 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time | 08.09.2022 | Amendment by applicant (claims and/or description) | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report | 08.09.2022 | Request for further processing filed | 08.09.2022 | Full payment received (date of receipt of payment) Request granted | 19.09.2022 | Decision despatched | Fees paid | Renewal fee | 25.02.2021 | Renewal fee patent year 03 | 25.02.2022 | Renewal fee patent year 04 | 27.02.2023 | Renewal fee patent year 05 | 27.02.2024 | Renewal fee patent year 06 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO02095006 (GENZYME CORP [US], et al) [A] 1-15 * claim 1 *; | [A]WO2015196179 (UNIV FLORIDA [US]) [A] 1-15 * page 17, line 24 - page 20, line 29; example 1; claims 1-41 *; | [A] - DOERFLER PHILLIP A ET AL, "Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease", RVSV(M DELTA 51)-M3 IS AN EFFECTIVE AND SAFE ONCOLYTIC VIRUS FOR CANCER THERAPY,, (20160101), vol. 27, no. 1, doi:10.1089/HUM.2015.103, ISSN 1557-7422, pages 43 - 59, XP002767258 [A] 1-15 * page 48, column l, paragraph 1 - page 54, column l, paragraph 1 * DOI: http://dx.doi.org/10.1089/hum.2015.103 | International search | [A]US2007161031 (TRINKLEIN NATHAN D [US], et al) [A] 49-52, 55-60* ; paragraph [0008] *; | [Y]US2010120152 (WOODDELL CHRISTINE I [US], et al) [Y] 4/1-3, 5/4/1-3, 6/5/4/1-3, 7/6/5/4/1-3, 8/1-3, 9/8/1-3, 10/9/8/1-3, 11/10/9/8/1-3, 12/1-3, 13/12/1-3, 14/13/12/1-3, 15/14/13/12/1-3 * ; paragraph [0060] *; | [Y]US2017218395 (BYRNE BARRY JOHN [US], et al) [Y] 1-3, 4/1-3, 5/4/1-3, 6/5/4/1-3, 7/6/5/4/1-3, 8/1-3, 9/8/1-3, 10/9/8/1-3, 11/10/9/8/1-3, 12/1-3, 13/12/1-3, 14/13/12/1-3, 15/14/13/12/1-3, 53-54 * ; paragraphs [0077], [0079], [0124] *; | [Y]US2017275649 (VANDENDRIESSCHE THIERRY [BE], et al) [Y] 1-3, 4/1-3, 5/4/1-3, 6/5/4/1-3, 7/6/5/4/1-3, 8/1-3, 9/8/1-3, 10/9/8/1-3, 11/10/9/8/1-3, 12/1-3, 13/12/1-3, 14/13/12/1-3, 15/14/13/12/1-3, 53-54 * ; paragraphs figure 20; [0012], [0024], [0027], [0029], [0090], [0156] * |